#USA #BD #Franklin Lakes #Surgery #Phasix Mesh

BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial

BD (Becton, Dickinson and Company), a premier global medical technology firm, has marked a critical milestone in its advanced tissue regeneration initiatives. The company has recently completed patient enrollment in the PREVENT clinical trial, a significant study that explores the use of Phasix™ Mesh for preventing incisional hernias—a common and unwelcome complication that can occur following abdominal surgeries.

The PREVENT trial stands out as the first large-scale randomized study focused on evaluating prophylactic reinforcement for incisional hernia prevention using a resorbable mesh. With the successful enrollment of 477 patients across 32 diverse sites in both the United States and Europe, this trial underscores a considerable unmet medical need in post-surgical care.

Rian Seger, worldwide president of Surgery at BD, explained the significance of the study: "PREVENT reflects our commitment to extending the impact of advanced tissue regeneration into new areas of patient care. By evaluating Phasix™ Mesh in hernia prevention, we are building on decades of innovation in abdominal wall surgery and generating evidence that could help broaden the role of regenerative technologies for patients at risk of post-surgical complications. We are grateful to the investigators, clinical sites, and patients whose participation made this achievement possible."

Key Objectives of the PREVENT Trial

The primary aim of this trial is to generate robust clinical evidence evaluating the effectiveness of Phasix™ Mesh in preventing incisional hernias following elective open midline abdominal surgery in patients deemed to be at high risk for developing these complications. Patients enrolled in the study will be monitored not only through to the study's primary endpoint at 24 months but also over a five-year period for longer-term safety and clinical outcome evaluations.

This study's design offers a structured framework for assessing the potential benefits of Phasix™ Mesh, allowing researchers to gather comprehensive data that may ultimately support a planned submission to the U.S. Food and Drug Administration (FDA). The incorporation of patient-centric outcomes into the analysis process is a significant innovation, aligning with contemporary trends in the medical field that emphasize reliability and effectiveness.

Broader Implications for Medical Technology

BD, which ranks among the world's largest standalone medical technology companies, operates with the overarching mission of advancing the world of health through innovations in areas including medical essentials, connected care, biopharma systems, and interventional technologies. The company is dedicated to supporting healthcare professionals on the front lines by developing transformative technologies, services, and solutions designed to optimize clinical operations and improve patient care.

With more than 60,000 employees operating globally, BD is well positioned to deliver billions of products annually, positively impacting healthcare worldwide. Collaboration with customers at every stage allows BD to enhance health outcomes while also focusing on cost reduction, clinical efficiency, safety improvements, and expanded access to care.

As the healthcare community eagerly anticipates the outcomes of the PREVENT trial, BD's commitment to innovative solutions in hernia prevention represents a meaningful step forward for surgical procedures, and could significantly enhance the quality of life for many patients recuperating from surgery.

In conclusion, the successful enrollment in the PREVENT trial illustrates BD's proactive approach in addressing critical healthcare challenges while maintaining a strong focus on advancing tissue regeneration technologies. As preliminary data emerges, the potential health benefits that could stem from Phasix™ Mesh and future medical innovations remain an exciting prospect for patients and healthcare providers alike.